alexa
Reach Us +1 218 451 2974
A Case of Methylenetetrahydrofolate Reductase Deficiency with Suspected Early-onset Dementia Associated with Hyperhomocysteinemia Due to Reduced Folate
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
  • Case Report   
  • J Alzheimers Dis Parkinsonism 2019, Vol 9(3): 467

A Case of Methylenetetrahydrofolate Reductase Deficiency with Suspected Early-onset Dementia Associated with Hyperhomocysteinemia Due to Reduced Folate

Kyoko Katsumura1*, Michiho Sodenaga1, Seiya Miyamoto3, Ouga Sasaki5, Tomoko Akiyama4, Osuke Migita2, Koji Hori1, and Hiroki Kocha1
1Department of Neuropsychiatry, St. Marianna University School of Medicine, Kawasaki, Japan
2Department of Pediatrics, St. Marianna University School of Medicine, Kawasaki, Japan
3Sakuragaoka Memorial Hospital, Tama, Japan
4Akiyama Neurosurgery Hospital, Yokohama, Japan
5Okayama Psychiatric Medical Center, Okayama, Japan
6Died 8 April 2019, Japan
*Corresponding Author: Kyoko Katsumura, Department of Neuropsychiatry, St. Marianna University School of Medicine 2-16-1 Sugao, Miyamae-ku, Kawasaki City Kanagawa, Japan, Tel: +81-44-977-8111, Fax: +81-44-976-3341, Email: [email protected]

Received Date: May 24, 2019 / Accepted Date: Jun 05, 2019 / Published Date: Jun 12, 2019

Abstract

A 46-year-old woman was admitted for suspected early-onset dementia. At the age of 20 years, she presented with seizures. She was subsequently diagnosed with major depressive disorder and schizophrenia. At age 43, she developed muscular hypotonia and gait disturbance. Three years later, on admission, laboratory studies showed marked hyperhomocysteinemia, hypomethioninemia, and decreased folate level. Brain magnetic resonance imaging revealed multiple cerebral infarction. She received supplements with folate and vitamin B6. After the treatment, serum homocysteine level was reduced but serum folate level was elevated above normal. A diagnosis of methylenetetrahydrofolate reductase (MTHFR) deficiency was considered, so we changed folate to betaine. Sequence analysis of the MTHFR gene demonstrated a missense c.677C>T (p.Ala222Val) mutation. Treatment with betaine resulted in reducing the folic acid level to normal and physical rehabilitation improved the muscular hypotonia. However, psychiatric symptoms such as cognitive impairment and depressive symptoms did not improve during the disease course. This case suggests that measurement of serum levels of homocysteine, methionine, and folate may be useful for identifying the cause of unexplained adult-onset epilepsy, progressive neurological distress, and early-onset multiple cerebral infarction

Keywords: Methylenetetrahydrofolate reductase deficiency; Hyperhomocysteinemia; Multiple cerebral infarction; Betaine; Early-onset dementia

Abbreviations

MTHFR: Methylenetetrahydrofolate Reductase; MMSE: Mini-Mental State Examination; WAIS-III: Wechsler Adult Intelligence Scale-Third Edition; CNS: Central Nervous System

Introduction

Methylenetetrahydrofolate Reductase (MTHFR) is a key enzyme in the folate-dependent remethylation of homocysteine [1]. It reduces 5, 10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the predominant circulating form of folate and donor of the methyl group in the remethylation of homocysteine to methionine. MTHFR deficiency is a rare autosomal recessive disease [2], with biochemical features that include homocystinuria, hyperhomocysteinemia, hypomethioninemia, and typically low plasma folate levels [3]. Its morbidity is unclear, but about 300 patients have been reported since its first description in 1972. Its clinical features are highly variable with regard to age of onset and severity and nature of the symptoms, and few cases of adult onset MTHFR deficiency have been described.

Here, we report the case of a 46-year-old woman with MTHFR deficiency and suspected early-onset dementia that was previously diagnosed with major depressive disorder and schizophrenia. The patient provided written informed consent for publication of this report.

Case Presentation

A 46-year-old Japanese woman was referred to our hospital for suspected early-onset dementia based on cognitive impairment and general functional decline. Growth and development in childhood had been normal. She had no history of drug or alcohol abuse or of nutritional deficiency, and no family history of mental disorder. She was nulliparous and her menstrual cycle was regular.

At the age of 20 years, she experienced several episodes of generalized seizures. She was given a diagnosis of epilepsy and was subsequently treated with antiepileptic drugs for 5 years. She later worked as a nursing assistant for 7 years.

At age 39, she was admitted to a psychiatric hospital with a diagnosis of major depressive disorder because of depressive symptoms triggered by financial challenges. After discharge, she had difficulty in finding regular employment and became socially withdrawn. At age 43, she developed muscular hypotonia and gait disturbance and became dependent on crutches. Two years later, she was emergently admitted to hospital because of stuporous state and hypothermia. She was diagnosed as having schizophrenia and was treated with antipsychotic drugs (aripiprazole and paliperidone). Soon after discharge, she was admitted to another hospital because of muscular weakness of all four limbs, upper limb tremor, hypersalivation, and loss of motivation. Reducing the dose of antipsychotic medications resulted in improvement of Extrapyramidal Symptoms (EPS), but cognitive dysfunction was observed. Brain computed tomography imaging showed diffuse atrophy of the cerebral cortex with ischemic changes. She was transferred to our hospital on suspicion of early-onset dementia for further investigation.

On admission, examination revealed dysarthria, EPS, global muscular weakness (left dominant), and gait disturbance. She also displayed psychiatric symptoms such as depressive mood, loss of motivation, lack of vitality, and insomnia. Electrocardiogram and electroencephalogram were normal. Five neuropsychological tests were performed. She scored 25/30 on the Mini-Mental State Examination (MMSE) [4,5] and 21/30 on the revised Hasegawa’s Dementia Scale [6]. Cognitive domains that showed decline on the Neurobehavioral Cognitive Status Examination [7] included attention and visuospatial cognition. Profiles on the Wechsler Adult Intelligence Scale-Third Edition (WAIS-III) [8] were full intelligence quotient (IQ) 60, verbal IQ 68, and performance IQ 57. Premorbid IQ was 115, which was estimated using the Japanese Adult Reading Test [9].

Laboratory evaluation revealed a decreased serum folate level of 1.4 ng/mL (normal range, 3.6-12.9 ng/mL). There was no megaloblastic anemia. Brain magnetic resonance imaging revealed multiple cerebral infarction located around the corona radiate, the left basal ganglia, and the pons on T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) images (Figure 1). A right putaminal hemorrhage was detected on T2 star-weighted images.

Figure 1: Axial and coronal T2-weighted and Fluid-Attenuated Version Recovery (FLAIR) Magnetic Resonance Imaging (MRI) images scans showing multiple cerebral infarcts located around the corona radiata and at the left basal ganglia (A-C). Axial T2 star- weighted images showing a right putaminal haemorrhage (D-F).

Additional tests were performed to determine the cause of the multiple cerebral infarction and low serum folate levels. The results were as follows: serum homocysteine, 77.8 nmol/mL (normal, 3.7- 13.5); methionine 16.8 nmol/mL (19.8-32.7), and pyridoxal 3.0 ng/mL (4.0-19.0). These results were suggestive of hyperhomocysteinemia. The patient had no hallucinations or delusions, so the antipsychotics were discontinued. She received folate and vitamin B6 supplements. After the treatment, serum homocysteine level decreased but the serum folate level was elevated above normal (>20 ng/mL). A diagnosis of MTHFR deficiency was considered, so we changed folate to betaine. Treatment with betaine (3,000 mg/day) lowered the folate level to normal and the serum level of homocysteine and methionine also normalized. We consulted our pediatricians and then performed MTHFR gene sequencing. The results showed a 677C>T polymorphism (p.Ala222Val, rs1801133 TT homozygous). MTHFR activity was not measured. Physical rehabilitation improved muscular hypotonia. However, psychiatric symptoms such as cognitive impairment and depressive symptoms did not improve during the disease course.

Discussion

MTHFR deficiency is the most common inborn error of folate metabolism and is a major cause of hereditary homocysteinemia [10]. Disease onset in MTHFR deficiency occurs mostly early in life and adult onset is rare [11]. Patients with severe MTHFR deficiency demonstrate a wide range of clinical symptoms but usually show progressive neurological distress within the two first decades of life [12]. Adolescent or adult-onset MTHFR deficiency may present with mental retardation, motor and gait disturbance, seizures, various psychiatric symptoms, and thrombosis [13]. Seizures are often initially seen in patients with adult-onset MTHFR deficiency [11,14,15] and the epileptic seizures that occurred in our patient at 20 years of age may have been the first clinical manifestation of the illness.

MTHFR deficiency is a severe disease that primarily affects the Central Nervous System (CNS), mainly because of defective myelination [16-18]. Our patient had intermediate hyperhomocysteinemia and multiple cerebral infarctions. Research has indicated that homocysteine can trigger neuronal damage via oxidative stress, DNA damage, and activation of pro-apoptotic factors in cell culture and animal models [19,20]. It is also believed that hyperhomocysteinemia induces endothelial cell damage, reduces vascular compliance, and alters the process of hemostasis [20]. Moreover, homocysteine is a recognized risk factor for atherosclerotic vascular disease and hypercoagulability states [20,21], although a meta-analysis of large unpublished datasets found no association between elevated homocysteine levels and risk of coronary artery disease [22]. Taken together, these findings suggest that hyperhomocysteinemia may have predisposed our patient, at least in part, to developing early-onset multiple cerebral infarctions.

A 677C>T polymorphism in the MTHFR gene as observed in our patient is a common genetic variant that encodes a thermolabile enzyme which is less active at higher temperatures [23]. Individuals who carry two copies of this variant (“TT homozygous”) tend to have reduce enzyme activity with higher homocysteine levels and lower serum folate levels [24].

Treatment approaches in the management of MTHFR deficiency are heterogeneous with regard to selection, combination, and dosage of drugs [11], but betaine is known to be the most effective therapeutic agent [25,26]. The beneficial effect of betaine in severe MTHFR deficiency is mediated through betaine-homocysteine methyltransferase with the use of an alternate methyl donor for remethylation of homocysteine to methionine [17]. Case reports suggest that treatment with betaine may prevent further cognitive decline in surviving symptomatic patients and may prevent cognitive damage and death if treatment is initiated early [14,27,28]. In our patient, biochemical improvement was seen after betaine treatment, but it was not effective for cognitive impairment or depressive symptoms, suggesting that the cognitive damage had become irreversible. We did not use any antidepressant drugs in this case, but they might have had some benefits on depressive symptoms.

MTHFR deficiency is not detected by current routine infantile mass screening testing for congenital amino acid metabolic disease in Japan, since it checks for hypermethioninemia, and the plasma methionine level is usually low or within normal range in affected patients [29]. Unless clinicians maintain a high index of suspicion and are familiar with the various clinical manifestations, this diagnosis is often missed [2]. Thus, because of the need for to start effective treatment as early as possible, MTHFR deficiency should be considered when investigating atypical progressive neurological distress, epilepsy, and cerebral infarction with decreased serum folate.

Conclusion

The fact that severe MTHFR deficiency may occur late in adulthood has strong practical implications. Screening for serum levels of homocysteine, methionine, and folate may be useful for identifying the cause of unexplained adult-onset epilepsy, progressive neurological distress, and early-onset multiple cerebral infarction. Specific treatment should be started early, before irreversible CNS damage occurs.

Conflicts of Interest

Dr. Hori received lecture fees from Eisai Co. Ltd., Pfizer Japan Inc., Novartis Pharma KK, Daiici Sankyo Inc., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical KK, Yoshitomi Yakuhin Co, Meiji Seika Pharma Co. Ltd., and Mitsubishi Tanabe Pharma Co. All other authors declare no conflict of interest.

Author Contributions

All authors contributed equally to the planning and conduct of the work described in the article. Drs. Katsumura, Sodenaga, and Miyamoto were mainly responsible for drafting this report. Other authors critically checked the drafts.

References

Citation: Katsumura K, Sodenaga M, Miyamoto S, Sasaki O, Akiyama T, et al. (2019) A Case of Methylenetetrahydrofolate Reductase Deficiency with Suspected Early-onset Dementia Associated with Hyperhomocysteinemia Due to Reduced Folate. J Alzheimers Dis Parkinsonism 9:467.

Copyright: © 2019 Katsumura K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Select your language of interest to view the total content in your interested language

Post Your Comment Citation
Share This Article
Relevant Topics
Recommended Conferences
  • 14th World Congress on Advances in Alzheimers and Dementia

    October 23-24, 2019 Melbourne, Australia

  • 2nd International Conference on Bipolar Disorder: Depression and Psychiatry

    November 11-12, 2019 Istanbul, Turkey

Article Usage
  • Total views: 354
  • [From(publication date): 0-0 - Aug 17, 2019]
  • Breakdown by view type
  • HTML page views: 326
  • PDF downloads: 28
Top